Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a ...

Interleukin-1 (IL-1) is a pro-inflammatory cytokine that mediates a diverse range of effects, in both the immune system and the central nervous system. The tight regulatory control of the actions ...

Type 17 helper T cells (Th17) — a third class of T cells — and their major cytokine, interleukin-17, are essential for the defense against certain fungi, extracellular bacteria, and ...

Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increa ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.New ...

Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic ...

Interleukin-2 (IL-2) is a cytokine that is critical to the regulation of T-cell responses. IL-2 also has a huge range of immunostimulatory and immunomodulatory functions.

Researchers have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).

Low dose interleukin 2 is being tested as an immunomodulatory approach in neurodegenerative diseases. It increases the number and activity of regulatory T cells (Tregs) that suppress inflammation. At ...

The measurement of soluble interleukin-2 receptor (sIL-2R) levels in serum or plasma in adults has become a valuable tool for clinicians to assess immune function in vivo as part of the ...

T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression ...